Anzeige
Meldung des Tages: Goldchance mit Substanz: Warum dieses Projekt Investoren aufhorchen lässt

CSL Aktie (ADR) News

Aktie
WKN:  A115DF ISIN:  US12637N2045 US-Symbol:  CSLLY Branche:  Biotechnologie Land:  Australien
63,34 $
-0,91 $
-1,42%
53,694 € 20:05:40 Uhr
Depot/Watchlist
Marktkapitalisierung *
47,84 Mrd. €
Streubesitz
99,99%
KGV
25,63
Dividende
1,46 $
Dividendenrendite
3,07%
Faktor
2
Originalaktie
AU000000CSL8

CSL Aktie (ADR) News

07.12.25 - PR Newswire
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-​drlb) Over Five Years PR Newswire
28.10.25 - PR Newswire
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
21.10.25 - PR Newswire
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Recent RWE Data Show Cell-​Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-​Confirmed Influenza in Pediatric and Adult Populations Relative to ...
26.09.25 - PR Newswire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy PR Newswire
16.06.25 - PR Newswire
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-​gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-...
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
20.02.25 - PR Newswire
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-​Activated Factor XII Monoclonal Antibody for the ...
14.02.25 - PR Newswire
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-​amplifying mRNA COVID-19 Vaccine PR Newswire
13.02.25 - PR Newswire
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) PR Newswire
07.02.25 - PR Newswire
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-​drlb) Four Years Post-​Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with ...
06.02.25 - PR Newswire
Tavneos® (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-assoziierten Vaskulitis
Tavneos® (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-​assoziierten Vaskulitis PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +8,33%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »